Overview

The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This trial intends to evaluate Remimazolam Besylate's availability and safety compared with propofol.
Phase:
Phase 3
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
Yichang Humanwell Pharmaceutical Co.,Ltd
Treatments:
Propofol